{
  "nct_id": "NCT32177747",
  "indication": "Multiple Sclerosis",
  "phase": "Phase 1/2",
  "sample_size": 90,
  "duration_weeks": 19,
  "dropout_rate": 0.14,
  "blinding": "double-blind",
  "control_arm": "active comparator",
  "primary_endpoints": [
    "EDSS score change"
  ],
  "secondary_endpoints": [
    "New T2 lesions",
    "Relapse rate reduction"
  ],
  "outcome_summary": "Demonstrated superior efficacy compared to placebo",
  "success": 1,
  "start_date": "2022-01-11",
  "completion_date": "2022-05-24"
}